317 related articles for article (PubMed ID: 33109391)
1. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract][Full Text] [Related]
2. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
3. Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
Wood N; Morton M; Shah SN; Yao M; Barnard H; Tewari S; Suresh A; Kollikonda S; AlHilli MM
Gynecol Oncol; 2023 Feb; 169():55-63. PubMed ID: 36508759
[TBL] [Abstract][Full Text] [Related]
4. Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications.
van der Zanden V; van Soolingen NJ; Viddeleer AR; Trum JW; Amant F; Mourits MJE; Portielje JEA; Baalbergen A; Souwer ETD; van Munster BC
Eur J Surg Oncol; 2022 Apr; 48(4):896-902. PubMed ID: 34756760
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer.
Huang CY; Sun FJ; Lee J
Nutrition; 2020 Apr; 72():110642. PubMed ID: 31986319
[TBL] [Abstract][Full Text] [Related]
6. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM; Filippova OT; Cowan RA; Lakhman Y; Sarasohn DM; Nikolovski I; Torrisi JM; Ma W; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Chi DS; Long Roche K
Gynecol Oncol; 2020 Sep; 158(3):608-613. PubMed ID: 32518012
[TBL] [Abstract][Full Text] [Related]
7. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
[TBL] [Abstract][Full Text] [Related]
9. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.
Timmermans M; Sonke GS; Slangen BFM; Baalbergen A; Bekkers RLM; Fons G; Gerestein CG; Kruse AJ; Roes EM; Zusterzeel PLM; Van de Vijver KK; Kruitwagen RFPM; van der Aa MA
Eur J Surg Oncol; 2019 Aug; 45(8):1425-1431. PubMed ID: 31027945
[TBL] [Abstract][Full Text] [Related]
10. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
Kumar A; Moynagh MR; Multinu F; Cliby WA; McGree ME; Weaver AL; Young PM; Bakkum-Gamez JN; Langstraat CL; Dowdy SC; Jatoi A; Mariani A
Gynecol Oncol; 2016 Aug; 142(2):311-6. PubMed ID: 27235857
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
12. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
13. Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Shafa A; Watkins AB; McGree ME; Weroha SJ; Wahner Hendrickson AE; Block MS; Langstraat CL; McBane RD; Bakkum-Gamez JN; Kumar A
Gynecol Oncol; 2023 Sep; 176():36-42. PubMed ID: 37442024
[TBL] [Abstract][Full Text] [Related]
14. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
[TBL] [Abstract][Full Text] [Related]
15. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Cybulska P; Avery L; May T; Hogen L
Gynecol Oncol; 2022 Sep; 166(3):453-459. PubMed ID: 35820987
[TBL] [Abstract][Full Text] [Related]
16. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
[TBL] [Abstract][Full Text] [Related]
17. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
Ray MD; Deo SSV; Kumar L; Gaur MK
Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
[TBL] [Abstract][Full Text] [Related]
18. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinical effects of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Jiang Y; He W; Yang H; Su Z; Sun L
J BUON; 2018; 23(3):758-762. PubMed ID: 30003748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]